UE2316
UE2316 is an orally active and specific 11βHSD1 inhibitor. UE2316 significantly improves glucose tolerance and insulin sensitivity in uremic rats. UE2316 also exacerbates hepatic fibrosis in mice. UE2316 can be used in the research of diseases such as hepatic fibrosis, uremia and diabetes mellitus.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1274933-58-2
- Fòrmula: C19H17ClFN3OS
- Peso molecular:389.87
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
UE2316 (10 μM; 8 days) reverses the inhibitory effect of glucocorticoids on the expression of pro-fibrotic genes (Acta2, Col1a1) in primary hepatic stellate cell (HSC) culture systems derived from C57Bl/6J mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HSCs
-
Concentration:10 μM
-
Incubation Time:8 days
-
Result:Increased the mRNA levels of Acta2 and Col1a1.
UE2316 (20 mg/kg; s.c. osmotic pump; 2 weeks) improves glucose tolerance and insulin sensitivity in adenine (HY-B0152)-induced uremic rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (male, 7 weeks old, Adenine (HY-B0152)-induced uremia)[1]
-
Dosage:20 mg/kg
-
Administration:s.c. minipump; daily; 2 weeks
-
Result:Significantly improved glucose tolerance and insulin sensitivity in adenine-fed rats.
Showed no effect on renal failure parameters.
-
Animal Model:C57Bl/6J (male, adult, carbon tetrachloride-induced)[2]
-
Dosage:0.15% (in chow diet)
-
Administration:oral; 12-weeks
-
Result:Exacerbates liver fibrosis.
Delayed scar resolution.
Reduced plasma ALT and AST levels.
Chemical Information
-
No. CAS 1274933-58-2
-
Peso molecular 389.87
-
Fòrmula C19H17ClFN3OS
-
SMILES
O=C(C1=CSC(=C1)C=2C=NNC2)N3CCC(F)(C=4C=CC=CC4Cl)CC3
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Zou X, et al. 11Beta-hydroxysteroid dehydrogenase-1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis. Hepatology. 2018;67(6):2167-2181. [Content Brief]
[2]. Chapagain A, et al. Elevated hepatic 11β-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia. Proc Natl Acad Sci U S A. 2014;111(10):3817-3822. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)